Cytokine BAFF gene variation is associated with survival of patients with T-cell lymphomas

Clinical Cancer Research

Volumn 18, Issue 8, 2012, Pages 2250-2256

  Zhai, Kan ^a   Tian, Xiaobo ^c   Wu, Chen ^a   Lu, Ning ^b   Chang, Jiang ^a   Huang, Liming ^a   Zhang, Tongwen ^a   Zhou, Yuling ^a   Qiao, Yan ^a   Yu, Dianke ^a   Tan, Wen ^a   Chen, Jieping ^c   Lin, Dongxin ^a  

^a CANCER HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADULT; ARTICLE; B CELL ACTIVATING FACTOR GENE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SURVIVAL TIME; T CELL LYMPHOMA; TUMOR GENE;

B-CELL ACTIVATING FACTOR; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; LYMPHOMA, T-CELL; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SURVIVAL RATE;

EID: 84859880449     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3009     Document Type: Article

References (26)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-18.
2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-30.
3. Rizvi MA, Evens AM, Tallman MS, Nelson BP, Rosen ST. T-cell non-Hodgkin lymphoma. Blood 2006;107:1255-64. (Pubitemid 43242357)
4. Kimby E. Management of advanced-stage peripheral T-cell lymphomas. Curr Hematol Malig Rep 2007;2:242-8.
5. Piccaluga PP, Agostinelli C, Gazzola A, Mannu C, Bacci F, Sabattini E, et al. Prognostic markers in peripheral T-cell lymphoma. Curr Hematol Malig Rep 2010;5:222-8.
6. Xu PP, Wang Y, Shen Y, Wang L, Shen ZX, Zhao WL. Prognostic factors of Chinese patients with T/NK-cell lymphoma: a single institution study of 170 patients. Med Oncol. 2011 Jun 28. [Epub ahead of print].
7. Wu C, Xu B, Yuan P, Miao X, Liu Y, Guan Y, et al. Genome-wide interrogation identifies YAP1 variants associated with survival of small-cell lung cancer patients. Cancer Res 2010;70:9721-9.
8. Yang JJ, Cheng C, Yang W, Pei D, Cao X, Fan Y, et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA2009;301:393-403.
9. Huang YT, Heist RS, Chirieac LR, Lin X, Skaug V, Zienolddiny S, et al. Genome-wide analysis of survival in early-stage non-small-cell lung cancer. J Clin Oncol 2009;27:2660-7.
10. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002;2:465-75. (Pubitemid 37328738)
11. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003;21:231-64. (Pubitemid 37174532)
12. Schneider P, Tschopp J. BAFF and the regulation of B cell survival. Immunol Lett 2003;88:57-62. (Pubitemid 36835851)
13. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006;18:263-75. (Pubitemid 44287558)
14. Mackay F, Cancro MP. Travelling with the BAFF/BLyS family: are we there yet? Semin Immunol 2006;18:261-2. (Pubitemid 44382642)
15. Kawasaki A, Tsuchiya N, Fukazawa T, Hashimoto H, Tokunaga K. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 2002;3:424-9. (Pubitemid 41656542)
16. Nossent JC, Lester S, Zahra D, Mackay CR, Rischmueller M. Polymorphism in the 50 regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjogren's syndrome. Rheumatology (Oxford) 2008;47:1311-6.
17. Novak AJ, Slager SL, Fredericksen ZS, Wang AH, Manske MM, Ziesmer S, et al. Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. Cancer Res 2009;69:4217-24.
18. Novak AJ, Grote DM, Ziesmer SC, Kline MP, Manske MK, Slager S, et al. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 2006;24: 983-7. (Pubitemid 46638853)
19. Huard B, Schneider P, Mauri D, Tschopp J, French LE. T cell costimulation by the TNF ligand BAFF. J Immunol 2001;167:6225-31. (Pubitemid 33081551)
20. Wen L, Chen SJ, Zhang W, Ma HW, Zhang SQ, Chen L. hsBAFF regulates proliferation and response in cultured CD4(+) T lymphocytes by upregulation of intracellular free Ca(2+) homeostasis. Cytokine 2011;53:215-22.
21. Huard B, Arlettaz L, Ambrose C, Kindler V, Mauri D, Roosnek E, et al. BAFF production by antigen-presenting cells provides T cell co-stimulation. Int Immunol 2004;16:467-75. (Pubitemid 38313155)
22. Mackay F, Leung H. The role of the BAFF/APRIL system on T cell function. Semin Immunol 2006;18:284-9. (Pubitemid 44287556)
23. Ye Q, Wang L, Wells AD, Tao R, Han R, Davidson A, et al. BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses. Eur J Immunol 2004;34:2750-9. (Pubitemid 39430152)
24. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1.
25. Ferrer G, Hodgson K, Montserrat E, Moreno C. B cell activator factor and a proliferation-inducing ligand at the cross-road of chronic lymphocytic leukemia and autoimmunity. Leuk Lymphoma 2009;50: 1075-82.
26. Sutherland AP, Ng LG, Fletcher CA, Shum B, Newton RA, Grey ST, et al. BAFF augments certain Th1-associated inflammatory responses. J Immunol 2005;174:5537-44. (Pubitemid 40593194)